Intrathecal borrelia-specific antibody production may persist for years after successful treatment [4], whereas the levels of CXCL13 decrease rapidly after antibiotic treatment, and hence it might be suitable for monitoring of treatment response, and distinguishing an active infection from a past infection [24]. Here, CXCL13 is linked to infection.